Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Notice to Our Valued Users

Elsevier has made the difficult decision to close PracticeUpdate permanently. There will be no new content published, effective immediately. Although we are all disappointed by this news, we are incredibly grateful for your engagement and support over the years.

We thank the Editorial Boards, Advisory Boards, and Editorial Contributors for their many years of dedication to educating the healthcare community. Our appreciation extends to the many contributors who have shared their valuable time and expertise to help us parse the latest research over the years.

We encourage you to explore our other offerings such as ScienceDirect and ClinicalKey, which continue to provide valuable insights and information to help you excel in your practice.

If you have any questions or need assistance, please see the FAQs section or contact the support team. Thank you for being a part of the PracticeUpdate community!

Mark Hallett MD Editor-in-Chief

Nina F. Schor MD, PhD Advisory Board

Avindra Nath MD Associate Editor

See All Experts

featured

Published in Neurology

Journal Scan / Consensus and Guidelines · April 28, 2022

Evidence Regarding Aducanumab Use in Symptomatic Alzheimer Disease

Neurology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

Additional Info

Article Citation

Neurology

Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: A Report of the AAN Guidelines Subcommittee

Neurology 2022 Apr 12;98(15)619-631, GS Day, N Scarmeas, R Dubinsky, K Coerver, A Mostacero, B West, SR Wessels, MJ Armstrong

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Notice to Our Valued Users

Evidence Regarding Aducanumab Use in Symptomatic Alzheimer Disease

Additional Info

Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: A Report of the AAN Guidelines Subcommittee

Further Reading

Final Note From the Neurology Editors

Association of Health and Lifestyle Factors With Dementia Risk in Former Professional Soccer Players

Association of the Cervical Canal Area With Disability and Progression in People With MS

Directional Subthalamic Deep Brain Stimulation Better Improves Gait and Balance Disorders in Patients With Parkinson's Disease

Induction Cyclophosphamide With Maintenance Immunosuppression for High-Risk Myasthenia Gravis

Non-Invasive Continuous Oral Delivery of Solid Levodopa–Carbidopa for the Management of Parkinson's Disease

Low-Frequency Deep Brain Stimulation During Non-REM Sleep Modifies Memory Retention in Patients With Parkinson's Disease

Toward Personalized Dosing of B-Cell–Depleting Therapy

Safety and Efficacy of Intravenous Recombinant Human Prourokinase for Acute Ischaemic Stroke Within 4.5 Hours After Stroke Onset

Hypogammaglobulinemia and Severe Infections in Patients With MS on Anti-CD20 Agents

Risk of Hypertension in Patients With MS Treated With Teriflunomide vs Dimethyl Fumarate

Recently Updated